[
  {
    "ts": null,
    "headline": "DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplan",
    "url": "https://finnhub.io/api/news?id=1706cfd16c499ac3b40c19d2268d52bca7f5c669ad3d08b9bf6faf3f39802541",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769546940,
      "headline": "DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible",
      "id": 138275313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplan",
      "url": "https://finnhub.io/api/news?id=1706cfd16c499ac3b40c19d2268d52bca7f5c669ad3d08b9bf6faf3f39802541"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers",
    "summary": "Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.",
    "url": "https://finnhub.io/api/news?id=016c029863ceca3d956156f9ccea70c04c5fd5cec0c2a5ae73ccfb7d452ae0a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769543460,
      "headline": "3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers",
      "id": 138275301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.",
      "url": "https://finnhub.io/api/news?id=016c029863ceca3d956156f9ccea70c04c5fd5cec0c2a5ae73ccfb7d452ae0a6"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets FDA Approval for Blood Cancer Treatment",
    "summary": "Johnson & Johnson Gets FDA Approval for Blood Cancer Treatment",
    "url": "https://finnhub.io/api/news?id=881f0fecd41b45d4351d7abd6762de280379e2718ff230cecd0dc9f1c4189e45",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769531220,
      "headline": "Johnson & Johnson Gets FDA Approval for Blood Cancer Treatment",
      "id": 138282578,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson Gets FDA Approval for Blood Cancer Treatment",
      "url": "https://finnhub.io/api/news?id=881f0fecd41b45d4351d7abd6762de280379e2718ff230cecd0dc9f1c4189e45"
    }
  },
  {
    "ts": null,
    "headline": "J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units",
    "summary": "JNJ targets $100-$101B in 2026 sales, projecting faster growth in Innovative Medicine and MedTech despite looming patent losses",
    "url": "https://finnhub.io/api/news?id=793d9a82e4ee5738d6d1dca925450d8d880600f1a5295ec27675a301784b4e20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769529060,
      "headline": "J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units",
      "id": 138272452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ targets $100-$101B in 2026 sales, projecting faster growth in Innovative Medicine and MedTech despite looming patent losses",
      "url": "https://finnhub.io/api/news?id=793d9a82e4ee5738d6d1dca925450d8d880600f1a5295ec27675a301784b4e20"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile",
    "summary": "NEW BRUNSWICK, N.J., January 27, 2026--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communities in 2026.",
    "url": "https://finnhub.io/api/news?id=96503feb0504300730a211e0349fb24426bdb669c5c0fcdc5c78fddec6ed0cc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769518800,
      "headline": "Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile",
      "id": 138270064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., January 27, 2026--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communities in 2026.",
      "url": "https://finnhub.io/api/news?id=96503feb0504300730a211e0349fb24426bdb669c5c0fcdc5c78fddec6ed0cc5"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Lifts Johnson & Johnson (JNJ) Outlook After Solid Q4 and 2026 Guide",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. On January 23, Guggenheim analyst Vamil Divan raised his price target on Johnson & Johnson (NYSE:JNJ) to $240 from $227. The firm reiterated a Buy rating. The move followed what he described as “solid” fourth-quarter results, along […]",
    "url": "https://finnhub.io/api/news?id=3738559e6d10d76ce2c1643d81830fbe698392d9b08fc2eaaa9177f633152b96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769509331,
      "headline": "Guggenheim Lifts Johnson & Johnson (JNJ) Outlook After Solid Q4 and 2026 Guide",
      "id": 138269258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. On January 23, Guggenheim analyst Vamil Divan raised his price target on Johnson & Johnson (NYSE:JNJ) to $240 from $227. The firm reiterated a Buy rating. The move followed what he described as “solid” fourth-quarter results, along […]",
      "url": "https://finnhub.io/api/news?id=3738559e6d10d76ce2c1643d81830fbe698392d9b08fc2eaaa9177f633152b96"
    }
  },
  {
    "ts": null,
    "headline": "JNJ Delivers Strong 2026 Guidance Even as Policy Costs Loom",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) posted its fourth-quarter 2025 earnings on January 21 and followed it up with a 2026 outlook that came in ahead of Wall Street expectations. What stood out is that the guidance still looks […]",
    "url": "https://finnhub.io/api/news?id=d329197d577e1000b78f621eaac4d6467a92341102a629b76b84e46cd97fcff3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769509247,
      "headline": "JNJ Delivers Strong 2026 Guidance Even as Policy Costs Loom",
      "id": 138269259,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) posted its fourth-quarter 2025 earnings on January 21 and followed it up with a 2026 outlook that came in ahead of Wall Street expectations. What stood out is that the guidance still looks […]",
      "url": "https://finnhub.io/api/news?id=d329197d577e1000b78f621eaac4d6467a92341102a629b76b84e46cd97fcff3"
    }
  },
  {
    "ts": null,
    "headline": "5 robotic surgery trends to watch in 2026",
    "summary": "Soft tissue robotic systems designed to improve surgical precision are expanding into new specialties and increasing competition for longtime industry leader Intuitive Surgical.",
    "url": "https://finnhub.io/api/news?id=511d4a137076faa06d42977e620304c6994d0916fcd880b77e12db1aa04b4921",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769508000,
      "headline": "5 robotic surgery trends to watch in 2026",
      "id": 138270931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Soft tissue robotic systems designed to improve surgical precision are expanding into new specialties and increasing competition for longtime industry leader Intuitive Surgical.",
      "url": "https://finnhub.io/api/news?id=511d4a137076faa06d42977e620304c6994d0916fcd880b77e12db1aa04b4921"
    }
  },
  {
    "ts": null,
    "headline": "How A New Price Target Is Rewriting The Story For Johnson & Johnson (JNJ)",
    "summary": "What a Changing Price Target Signals for Johnson & Johnson The recent shift in analysts' price target for Johnson & Johnson puts fresh attention on how the market is reassessing the stock's risks, opportunities, and overall narrative. With the target no longer sitting where it once did, the change itself becomes a key data point in how sentiment is being reset around the company. Stay tuned to see how you can keep on top of these price target moves and the evolving story behind them. Stay...",
    "url": "https://finnhub.io/api/news?id=38a4385a1f0781acf05b4c11e6940ee7c15c2969396ca06a867c61116496e7ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769501242,
      "headline": "How A New Price Target Is Rewriting The Story For Johnson & Johnson (JNJ)",
      "id": 138268659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "What a Changing Price Target Signals for Johnson & Johnson The recent shift in analysts' price target for Johnson & Johnson puts fresh attention on how the market is reassessing the stock's risks, opportunities, and overall narrative. With the target no longer sitting where it once did, the change itself becomes a key data point in how sentiment is being reset around the company. Stay tuned to see how you can keep on top of these price target moves and the evolving story behind them. Stay...",
      "url": "https://finnhub.io/api/news?id=38a4385a1f0781acf05b4c11e6940ee7c15c2969396ca06a867c61116496e7ab"
    }
  },
  {
    "ts": null,
    "headline": "IBB: Beyond The 2025 Surge, Biotech Breakout",
    "summary": "iShares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=8d2093e4fbe4954a0995724673d028877e1a938b45a84289884c25a074dc7e55",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769490639,
      "headline": "IBB: Beyond The 2025 Surge, Biotech Breakout",
      "id": 138268876,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233342016/image_2233342016.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "iShares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=8d2093e4fbe4954a0995724673d028877e1a938b45a84289884c25a074dc7e55"
    }
  }
]